On Nov. 19, 2025, Precise Bio announced the first patient has been successfully treated with PB-001, the Company’s 3D-bio-printed corneal implant, at Rambam Medical Center in Haifa, Israel as part of its ongoing Phase 1 clinical trial. The procedure was performed on October 29, 2025, on a patient who was legally blind at the time of treatment and received the bio-implant in one eye.

This procedure marks the world’s first transplant of a cell based, functional 3D-bio-printed cornea, establishing a pivotal milestone for ophthalmology, regenerative medicine and the future of tissue engineering.

“This achievement marks a turning point for regenerative ophthalmology—a moment of real hope for millions living with corneal blindness,” said Aryeh Batt, Co-Founder and Chief Executive Officer of Precise Bio. “For the first time, a corneal implant manufactured entirely in the lab from cultured human corneal cells, rather than direct donor tissue, has been successfully implanted in a patient. Imagine a world where a single donor cornea can give rise to hundreds of lab-grown implants, transforming scarcity into abundance.

This milestone reflects over a decade of multidisciplinary innovation in cell biology, biomaterials, and 3D bioprinting, and demonstrates the potential of our platform to make corneal transplantation scalable and accessible worldwide. We look forward to advancing the clinical evaluation of PB-001 in our ongoing Phase 1 trial.”

Unlike traditional grafts that rely on limited human donors, PB-001 is engineered to replicate the optical clarity and biomechanical properties of the native cornea. The implant is manufactured at Precise Bio’s GMP facility located in Sheba Medical Center, using the Company’s robotic 3D-bio-fabrication system. Within the facility, Precise Bio isolates, cultivates, and prints corneal cells into a precisely layered structure that integrates with the patient’s own tissue.

The design aims to deliver improved visual outcomes, lower complication rates, and consistent quality, while also enabling long-term cryopreservation for streamlined logistics and a sustainable solution to the global shortage affecting more than 13 million patients awaiting corneal tissue.

Precise Bio is a clinical-stage regenerative medicine company pioneering a proprietary 3D-bio-fabrication platform that integrates cell biology, and biomaterials to produce clinical-grade human tissues under GMP conditions. Its lead program, PB-001, is the world’s first bio-printed corneal implant to enter human clinical trials, with additional ophthalmology and advanced tissue programs in development.